ArticleHeliyon2020
Association of promoter methylation of
Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Clinical value of combinedOncology reviews · 2026Pooled it
- Detection ofMolecular and clinical oncology · 2025Article
- Mesoporous polydopamine nanoparticles coated with metal-polyphenol networks for demethylation therapy of lung cancer.Medical oncology (Northwood, London, England) · 2025Article
- Expression Pattern Study of miR-200a and XIAP Gene in the Non-small Cell Lung Cancer Patients’ BloodIranian biomedical journal · 2025Article
- MTTL3 upregulates microRNA-1246 to promote occurrence and progression of NSCLC via targeting paternally expressed gene 3.Molecular therapy. Nucleic acids · 2021Article
- Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung carcinoma (NSCLC) incidence and progression is increasing because of genetic and epigenetic changes. The mutations in the Kirsten rat sarcoma (
methodsNon-small cell lung carcinoma patients (n = 100) and equal number of healthy controls were assessed for activating
resultsThe frequency of mutations in Kirsten rat sarcoma (
conclusionsThe aberrant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.